Abstract
Purpose
The purpose of the study was to evaluate the pharmacokinetics of 68Ga-DOTATOC in order to ascertain which parameters have the greatest impact on the global DOTATOC standardised uptake value (SUV), defined as the mean SUV of the last frame of the dynamic study 55–60 min p.i.
Methods
Twenty-two patients with 74 metastatic lesions were examined with dynamic 68Ga-DOTATOC PET studies. Standardised uptake values (SUVs) were calculated for all frames following the injection of the tracer. We defined global SUV as the mean SUV of the last frame (frame duration 5 min) of the dynamic study 55–60 min p.i. A two-tissue compartment model with a blood compartment was used for the evaluation of the rate constants k 1 (receptor binding), k 2 (displacement from the receptor), k 3 (cellular internalisation), k 4 (cellular externalisation) and fractional blood volume (Vb). Furthermore, a non-compartmental model was applied for calculation of the fractal dimension (FD) of the time-activity curves based on the box counting procedure.
Results
Qualitative analysis revealed increased uptake of 68Ga-DOTATOC in 21/22 patients and in 72/74 lesions. The SUV for 68Ga-DOTATOC was highly variable, with a range from 0.877 to 28.07 (mean 8.73). The highest uptake was measured in a patient with a NET of the pancreas and the lowest in a patient with a medullary thyroid carcinoma (MEN II). The quantitative evaluation based on the compartmental analysis revealed high receptor binding (k 1) and internalisation (k 3) for 68Ga-DOTATOC, and low cellular externalisation (k 4) as well as a relatively low fractional blood volume (Vb). The FD values varied from 1.10 to 1.45, with a mean of 1.33. No significant linear correlation was found for k 1 and k 3. A low, linear correlation was noted for k 1 and Vb (r=0.25,p=0.03), and there was a significant non-linear correlation between SUV and FD (r=0.74, p<0.001). Best subset analysis demonstrated that k 1 had the greatest impact on the global SUV, followed by Vb and k 3.
Conclusion
DOTATOC uptake in NETs is mainly dependent on k 1 (receptor binding) and Vb (fractional blood volume). Pharmacokinetic data analysis can help to separate blood background activity (Vb) from the receptor binding (k 1), which may help to optimise planning of 90Y-DOTATOC therapy.
Similar content being viewed by others
References
Kaltsas G, Besser M, Grossman A. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004;25:458–511
Reubi JC, Laissue J, Waser B, Horisberger U, Schaer JC. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Ann N Y Acad Sci 1994;733:122–37
Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623–48
Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, Burger C, Heichel T, Willeke F, et al. Dynamic PET18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med 2001;42:713–20
Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998;25:79–83
Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 2004;25:568–80
De Jong M, Breeman WA, Bernard BF, van Gameren A, de Bruin E, Bakker WH, et al. [DOTA0,TYR3] octreotide is dependent on the peptide amount. Eur J Nucl Med 1999;26:693–8
De Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24:368–71
Bohuslavizki KH, Brenner W, Braunsdorf WE, Behnke A, Tinnemeyer S, Hugo HH, et al. Somatostatin receptor scintigraphy in the differential diagnosis of meningioma. Nucl Med Commun 1996;17:302–10
Maecke H, Hofmann M, Haberkorn U. 68-Ga-labeled peptides in tumor imaging. J Nucl Med 2005;46:172S–8S
Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000;7:971–94
Kontaxakis G, Strauss LG, Thireou T, Ledesma-Carbayo MJ, Santos A, Pavlopoulos SA et al. Iterative image reconstruction for clinical PET using ordered subsets, median root prior, and a web-based interface. Mol Imaging Biol 2002;4:219–31
Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of (68Ga)-DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) kinetics in patients with meningiomas J Nucl Med 2005;46:763–9
Burger C, Buck A. Requirements and implementations of a flexible kinetic modeling tool. J Nucl Med 1997;38:1818–23
Ohtake T, Kosaka N, Watanabe T, Yokoyama I, Moritan T, Masuo M,, et al. Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs. J Nucl Med 1991;32:1432–8
Dimitrakopoulou–Strauss A, Strauss LG, Mikolajczyk K, Burger C, Lehnert T, Bernd L, et al. On the fractal nature of dynamic positron emission tomography (PET) studies. World J Nucl Med 2003;2:306–13
Hofmann M, Maecke H, Börner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751–7
Baish JW, Jain RK. Fractals and cancer. Cancer Res 2001;61:8347–50
Majumdar S, Link TM, Millard J, Lin JC, Augat P, Newitt D, et al. In vivo assessment of trabecular bone structure using fractal analysis. Med Phys 2000;27:2594–9
Kuikka JT, Hartikainen P. Heterogeneity of cerebral blood flow: a fractal approach. Nuklearmedizin 2000;39:37–42
Acknowledgements
This work was supported by the DFG grants HA2901/3-1 and 3-2 from the Deutsche Forschungsgemeinschaft.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Koukouraki, S., Strauss, L.G., Georgoulias, V. et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 33, 460–466 (2006). https://doi.org/10.1007/s00259-005-0006-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-005-0006-1